Please use this identifier to cite or link to this item: https://ninho.inca.gov.br/jspui/handle/123456789/13847
Title: A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials
Authors: Vigorito, Afonso Celso
Bouzas, Luis Fernando da Silva
Moreira, Maria Cláudia Rodrigues
Funke, Vaneuza Araújo Moreira
Colturato, Vergilio Antonio Rensi
Pedro, Andréia
Souza, Clarissa Vasconcellos de
Nunes, Elenaide Coutinho
Miranda, Eliana Cristina Martins
Camacho, Kátia
Mauad, Marcos Augusto
Correa, Maria Elvira Pizzigatti
Silva, Márcia Matos
Sousa, Mair Pedro de
Tavares, Rita de Cássia Barbosa da Silva
Lee, Stephanie Joi
Flowers, Mary Evelyn Dantas
Keywords: Transplante de Células-Tronco Hematopoéticas
Hematopoietic Stem Cell Transplantation
Síndrome de Bronquiolite Obliterante
Bronchiolitis Obliterans Syndrome
Conferência para Desenvolvimento de Consenso dos NIH
Consensus Development Conference, NIH
Issue Date: 2011
Abstract: BACKGROUND: New criteria for the diagnosis and classification of chronic graft-versus-host disease were developed in 2005 for the purpose of clinical trials with a consensus sponsored by the National Institute of Health. OBJECTIVES: The aim of this study is to present the results of a multicenter pilot study performed by the Brazil-Seattle chronic graft-versus-host disease consortium to determine the feasibility of using these criteria in five Brazilian centers. METHODS: The study was performed after translation of the consensus criteria into Portuguese and training. A total of 34 patients with National Institute of Health chronic graft-versus-host disease were enrolled in the pilot study between June 2006 and May 2009. RESULTS: Of the 34 patients, 26 (76%) met the criteria of overlap syndrome and eight (24%) the classic subcategory. The overall severity of disease was moderate in 21 (62%) and severe in 13 (38%) patients. The median time from transplant to onset of chronic graft-versus-host disease was 5.9 months (Range: 3 - 16 months); the median time for the overlap syndrome subcategory was 5.9 months (Range: 3 - 10 months) and for the classic subcategory, it was 7.3 months (Range: 3 - 16 months). At a median follow up of 16.5 months (Range: 4 - 39 months), overall survival was 75%. CONCLUSIONS: It was feasible to use the National Institute of Health consensus criteria for the diagnosis and scoring of chronic graft-versus-host disease in a Brazilian prospective multicenter study. More importantly, a collaborative hematopoietic cell transplantation network was established in Brazil offering new opportunities for future clinical trials in chronic graft-versus-host disease and in other areas of research involving hematopoietic stem cell transplantation.
URI: https://ninho.inca.gov.br/jspui/handle/123456789/13847
ISSN: 1806-0870
Appears in Collections:Hospital do Câncer I (HCI)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.